This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

OPKO Announces Successful Confirmation Of 4Kscore™ Algorithm In The United States

Stocks in this article: OPK

OPKO Health, Inc. (NYSE:OPK) announced the successful completion of the calibration confirmation phase of the 4Kscore™ test clinical validation study currently underway at 21 urology clinics in the United States.

The OPKO 4Kscore™ test clinical validation protocol involves two parts: a calibration confirmation phase and a validation phase. The calibration confirmation phase evaluated the applicability of the 4Kscore™ algorithm, developed using banked samples from European studies, to the OPKO study samples collected in the United States and shipped directly to OPKO Lab in Nashville, TN for testing. The results confirmed the validity of the algorithm. The study is now more than 50% complete toward the final goal of 1,200 subjects. These results support the U.S. launch of the 4Kscore™ test in March 2014.

“We are extremely pleased that results of the calibration phase confirmed the 4Kscore™ algorithm is an accurate predictor of prostate cancer, and especially aggressive disease,” said David Okrongly, President of OPKO Diagnostics. “The reproducibility of the algorithm speaks to the robustness of the biomarkers used in the 4Kscore™ algorithm, as well as the quality of the multiple clinical studies published in peer-reviewed journals.”

“These results reinforce our belief that the 4Kscore™ test will be an important addition to the urologists’ means of assessing a patient’s risk for aggressive prostate cancer as well as an important new diagnostic product for OPKO,” said Phillip Frost, M.D., OPKO's Chairman and Chief Executive Officer.

About the 4Kscore™ Test

The 4Kscore™ is a convenient blood test that measures the serum levels of four different prostate-derived kallikrein proteins: total PSA, free PSA, intact PSA and hK2. Levels of these biomarkers are combined with a patient's age and digital rectal exam (DRE) status using a proprietary algorithm to calculate the probability of a finding of aggressive prostate cancer. The 4Kscore™ test is based on over a decade of research of the four kallikrein panel of biomarkers conducted by scientists at Memorial Sloan Kettering Cancer Center and leading research centers in Europe on over 10,000 patients. The information provided by the 4Kscore™ test can help facilitate the shared decision-making process between urologist and patient in determining the advisability of a prostate biopsy.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,489.93 -188.77 -1.07%
S&P 500 2,042.34 -14.75 -0.72%
NASDAQ 4,720.6940 -51.0690 -1.07%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs